CLINICAL TRIALS PROFILE FOR TIROSINT-SOL

All Clinical Trials for TIROSINT-SOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01832753 ↗	Treatment Trial of Subclinical Hypothyroidism in Down Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	2013-01-01	The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.
NCT01832753 ↗	Treatment Trial of Subclinical Hypothyroidism in Down Syndrome	Completed	Children's Hospital of Philadelphia	N/A	2013-01-01	The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.
NCT02567877 ↗	Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?	Recruiting	Charite University, Berlin, Germany		2016-11-01	Patients taking thyroid hormone replacement after thyroid removal surgery often report feeling differently than they did prior to taking thyroid hormone. The symptoms can include fatigue, worsening mood or subjective "brain fog" where the patient feels like their thinking is just not as sharp as it was previously. Multiple studies have found that patients taking thyroid hormone replacement have a diminished quality of life compared to matched controls. Previous studies have suggested that the type of deiodinase (DIO) polymorphism a patient has, which is responsible for converting the thyroid hormone T4 into the more biologically active T3, may contribute to their overall cognition and sense of well-being. The Investigators aim to determine if the type of deiodinase polymorphism a patient has contributes to the patient's cognition and overall sense of well-being after surgery and thyroid hormone replacement. Objective: Determine if patients with the deiodinase type 2 CC polymorphism have objective differences in working memory (N-back test is primary endpoint), cognitive function and sense of well-being after thyroidectomy when placed on standard thyroid hormone replacement therapy. Hypotheses: (1) Patients with the deiodinase type 2 CC polymorphism will have worse working memory (N-back test is primary endpoint), cognitive function and sense of well-being on standard thyroid hormone replacement therapy after thyroidectomy compared with before thyroidectomy. (2) Patients with the deiodinase type 2 TT or TC polymorphism will have no differences in working memory, cognitive function or sense of well-being on standard thyroid hormone replacement before and after thyroidectomy.

Clinical Trial Conditions for TIROSINT-SOL

Condition Name

Condition Name for TIROSINT-SOL
Intervention	Trials
Hypothyroidism	4
Congenital Hypothyroidism	1
Down Syndrome	1

Condition MeSH

Condition MeSH for TIROSINT-SOL
Intervention	Trials
Hypothyroidism	7
Down Syndrome	2
Congenital Hypothyroidism	1

Clinical Trial Locations for TIROSINT-SOL

Trials by Country

Trials by Country for TIROSINT-SOL
Location	Trials
United States	14
Italy	1

Trials by US State

Trials by US State for TIROSINT-SOL
Location	Trials
California	2
District of Columbia	2
Texas	1
Missouri	1
Washington	1

Clinical Trial Progress for TIROSINT-SOL

Clinical Trial Phase

Clinical Trial Phase for TIROSINT-SOL
Clinical Trial Phase	Trials
Phase 4	5
N/A	1

Clinical Trial Status

Clinical Trial Status for TIROSINT-SOL
Clinical Trial Phase	Trials
Recruiting	4
Completed	2
Unknown status	1

Clinical Trial Sponsors for TIROSINT-SOL

Sponsor Name

Sponsor Name for TIROSINT-SOL
Sponsor	Trials
IBSA Institut Biochimique SA	2
University of Colorado, Denver	1
Meyer Children's Hospital	1

Sponsor Type

Sponsor Type for TIROSINT-SOL
Sponsor	Trials
Other	6
Industry	3
NIH	1